Beckman Coulter Life Sciences wows the crowds at INTERPHEX 2024 with the spectacular debut of the QbD1200+ Total Organic Carbon (TOC) Analyzer. Offering unparalleled efficiency, simplicity, and data security, this groundbreaking innovation is set to redefine industry standards.
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, makes pharmaceutical and biopharmaceutical analysis faster and simpler with more robust data in launch of the QbD1200+ Total Organic Carbon (TOC) Analyzer. Offering simplified validation and reporting on encrypted data, it is designed to support 21 CFR Part 11 requirements and major global pharmacopeia regulations: USP, EP, JP, IP, KP.
“As pioneers in TOC analyzers, we are able to uniquely understand and respond to the evolving needs of customers,” said Product Manager Matthieu Chausseau. “With a relentless mission to simplify and accelerate workflows, we designed the intuitive QbD1200+ Laboratory TOC Analyzer to make measuring and analyzing total organic carbon simple, reproducible and intuitive, all with one reagent, creating a low total cost of ownership and peace of mind.”
The new analyzer features a digital non-dispersive infrared sensor (NDIR) with auto-correct drift to ensure long-term stability. It delivers reliable and reproducible results with control of the UV reactor temperature, dynamic endpoint detection and reduced sample-to-sample carryover. To help minimize maintenance and simplify workflows, 7 different sensors enable automatic system checks each time the instrument is powered on and monitor the instrument continuously.
An active directory allows encrypted data to be exported to a shared network directory to keep auditable information safe, secure, and paperless without the need for a PC. The intuitive user interface along with the large color touchscreen facilitates daily operations, simplifying workflows and making it easy to use while reducing the need for intensive personnel training in laboratories.
The QbD1200+ Laboratory TOC Analyzer, for pharmaceutical and biopharmaceutical use only, launches at the 2024 INTERPHEX conference in New York City on April 17, 2024
